Merck, Keytruda and Eisai

Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. | Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way.
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
Merck sees 2025 launch for simpler version of cancer drug Keytruda
Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year.
Merck’s Keytruda Combo Fails to Extend Survival in Phase III GI Cancer
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against its limits after racking up around 50 approvals since getting its first FDA nod in September 2014.
Merck, Eisai's combination drug fails in late-stage trial for esophageal cancer
Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a type of esophageal cancer in a late-stage trial. The trial was studying U.S. drugmaker Merck's blockbuster immunotherapy Keytruda and Eisai's Lenvima,
Merck and Eisai report mixed results in Phase 3 cancer trial
Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, which evaluated the efficacy of the combination therapy KEYTRUDA and LENVIMA for patients with advanced gastroesophageal adenocarcinoma.
Is Merck & Co., Inc. (MRK) the Best Dow Stocks to Buy Right Now?
We recently published a list of 12 Best Dow Stocks to Buy Right Now. In this article, we are going to take a look at where ...
Merck & Co. Inc. stock underperforms Friday when compared to competitors
Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.
Kennedy would keep legal fees from Merck cases if confirmed
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...
Jim Cramer Says Merck & Co., Inc. (MRK) ‘Needs To Have China Be Less Of Our Enemy’
We recently published an article titled Jim Cramer Discusses These 18 Stocks & President Trump’s $500 Billion AI Plan. In ...
Merck & Co.’s Accelerated Keytruda Launch and Strategic Updates Bolster Long-term Growth Prospects
Analyst Akash Tewari of Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), retaining the price target of ...
Merck: 3x Pipeline And Undervaluation Make It A Buy
Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...
Is Merck & Co., Inc. (MRK) the Most Reliable Dividend Stock to Buy According to Hedge Funds?
We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...
GlobalData on MSN2d
Merck and Opentrons to automate assay kits on custom workstation
Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...
Merck's SWOT analysis: stock outlook amid oncology competition, pipeline growth
Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...